Z

Zymeworks
D

ZYME

14.380
USD
0.38
(2.71%)
مغلق
حجم التداول
15,933
الربح لكل سهم
-2
العائد الربحي
-
P/E
-10
حجم السوق
990,458,824
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ADAP
    -0.01800
    (-3.11%)
    0.56000 USD
    B
    BEAM
    -2.705
    (-8.16%)
    30.445 USD
    B
    BLUE
    -2.93000
    (-41.68%)
    4.10000 USD
    C
    CRIS
    -0.03400
    (-1.09%)
    3.07600 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    F
    FATE
    -0.13500
    (-8.74%)
    1.41000 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: Zymeworks

القطاع: Healthcare
الصناعة: Biotechnology
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.